AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Polynovo Ltd (ASX:PNV)
1.26 AUD
+0.040 3.279%Sponsored Reports
Loading...
| Previous Close (in AUD) | 1.22 |
|---|---|
| Change | +0.040 3.279% |
| 52 W H/L (in AUD) | 2.780/0.930 |
| EBITDA (in AUD) | 8.683M |
| PE Ratio | 122.00 |
| Volume | 4989738 |
| Diluted Eps TTM | 0.01 |
| Total Assets (in AUD) | 109.167M |
|---|---|
| Total Liabilities (in AUD) | 37.043M |
| Revenue TTM (in AUD) | 115.578M |
| Cash (in AUD) | 45.907M |
| Market Cap (in AUD) | 842.829 M |
| Revenue Per Share TTM | 0.167 |
| Gross Profit TTM (in AUD) | 99.856M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Polynovo Ltd
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products. The company was formerly known as Calzada Limited and changed its name to PolyNovo Limited in November 2014. PolyNovo Limited was incorporated in 1998 and is headquartered in Port Melbourne, Australia.
Employees: 282
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Jan-Marcel Gielen C.A. | CFO & Company Sec. | NA |
| 2. | Dr. David McQuillan Ph.D. | Chief Technical & Scientific Officer | NA |
| 3. | Mr. Swami Raote BPHARM, M.B.A. | CEO & Director | NA |
| 4. | Mr. Ahmed Hassan | Director of Operations | NA |
| 5. | Ms. Teena Chadha | APAC Marketing & Distributor Mang. | NA |
| 6. | Ms. Monica Benyk | HR Mang. | NA |
| 7. | Dr. Tim Moore | Principal Scientist | NA |
| 8. | Mr. Edward Graubart | Sr. VP of Sales & Marketing (Americas) | NA |
| 9. | Mr. Jan-Marcel Gielen C.A. | CFO & Company Secretary | NA |
| 10. | Mr. Philip Scorgie | Chief Information Officer | NA |
Peers
Sector: Healthcare
Industry: Medical Devices
| Company | Change (AUD) | Price (AUD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
COH
Cochlear Ltd |
+3.060 0.996% | 308 | 54.460 | 44.843 | 8.700 | 10.531 | 8.459 | 32.699 |
|
EBR
Ebr Systems Inc CDR |
+0.015 1.210% | 1.25 | 0.000 | 0.000 | 0.000 | 20.726 | 0.000 | -3.679 |
|
IMR
Imricor Medical Systems Inc |
+0.020 1.544% | 1.32 | 0.000 | 0.000 | 434.198 | 3.972 | 269.432 | -2.603 |
|
AVH
Avita Therapeutics Inc |
+0.045 2.679% | 1.705 | 0.000 | 5.233 | 3.260 | 7.169 | 2.228 | -10.054 |
Income Statement
(Currency in AUD)| Breakdown | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 | 30-06-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -4.933M | -1.151M | -4.55M | -4.127M | -3.19M |
| Minority Interest | - | - | - | - | - |
| Net Income | -4.925M | -1.193M | -4.605M | -4.194M | -1.816M |
| Selling General Administrative | 50.845M | 28.576M | 24.055M | 19.565M | 11.867M |
| Gross Profit | 60.808M | 39.237M | 27.603M | 20.453M | 12.055M |
| Reconciled Depreciation | 2.037M | 1.589M | 0.921M | 0.837M | 0.31M |
| Ebit | -4.747M | 0.54M | -4.328M | -4.109M | -4.564M |
| Ebitda | -2.71M | 2.129M | -3.407M | -3.272M | -4.254M |
| Depreciation And Amortization | 2.037M | 1.589M | 0.921M | 0.837M | 0.31M |
| Operating Income | -5.089M | 0.54M | -4.23M | -4.045M | -4.564M |
| Other Operating Expenses | 47.029M | 26.826M | 23.163M | 18.126M | 17.913M |
| Interest Expense | 0.186M | 0.315M | 0.223M | 0.018M | 0.018M |
| Tax Provision | -0.009M | 0.042M | 0.055M | 0.067M | 0M |
| Interest Income | 0.87M | 0.001M | 0.001M | 0.059M | 0.345M |
| Net Interest Income | 0.155M | -0.315M | -0.32M | 0.017M | 0.334M |
| Income Tax Expense | -0.009M | 0.042M | 0.055M | 0.067M | -1.374M |
| Total Revenue | 65.241M | 41.44M | 29.158M | 22.156M | 13.349M |
| Total Operating Expenses | 66.993M | 39.494M | 30.75M | 24.593M | 16.619M |
| Cost Of Revenue | 4.434M | 2.203M | 1.555M | 1.704M | 1.294M |
| Total Other Income Expense Net | 1.096M | -0.58M | -1.083M | 0.095M | 1.374M |
| Net Income From Continuing Ops | -4.925M | -1.193M | -4.605M | -4.194M | -3.19M |
| Net Income Applicable To Common Shares | -4.925M | -1.193M | -4.605M | -4.194M | -3.19M |
Balance Sheet
(Currency in AUD)| Breakdown | 30-06-2024 | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 |
|---|---|---|---|---|---|
| Total Assets | 109.167M | 92.621M | 34.972M | 38.339M | 37.857M |
| Intangible Assets | 0.909M | 1.157M | 1.404M | 1.652M | 1.9M |
| Other Current Assets | 3.301M | 0.307M | 0.146M | 0.146M | 0.783M |
| Total Liab | 37.043M | 27.238M | 17.256M | 15.987M | 14.045M |
| Total Stockholder Equity | 72.124M | 65.383M | 17.715M | 22.352M | 23.812M |
| Other Current Liab | 14.114M | 9.929M | 5.932M | 6.835M | 7.863M |
| Common Stock | 191.601M | 191.591M | 139.431M | 139.251M | 139.071M |
| Capital Stock | 191.601M | 191.591M | 139.431M | 139.251M | 139.071M |
| Retained Earnings | -116.117M | -121.378M | -116.454M | -115.261M | -110.656M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 0.742M | 0.626M | 0.62M | 0.142M |
| Cash | 45.907M | 46.847M | 6.102M | 7.689M | 11.648M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 23.247M | 12.667M | 7.756M | 8.65M | 9.475M |
| Current Deferred Revenue | 0.206M | -1.89M | -1.834M | -2.875M | -5.628M |
| Net Debt | -30.527M | -30.803M | 4.892M | 2.308M | -1.616M |
| Short Term Debt | 2.535M | 1.89M | 1.788M | 2.875M | 5.628M |
| Short Long Term Debt | 1.888M | 1.398M | 1.33M | 2.525M | 5.304M |
| Short Long Term Debt Total | 15.38M | 16.044M | 10.994M | 9.997M | 10.032M |
| Other Stockholder Equity | - | -70.213M | -22.977M | -23.989M | -28.414M |
| Property Plant Equipment | - | 23.368M | 16.752M | 19.823M | 16.537M |
| Total Current Assets | 79.295M | 67.354M | 16.19M | 16.244M | 19.278M |
| Long Term Investments | 0.573M | 0.559M | 0.297M | 0.144M | 0.142M |
| Short Term Investments | 0.05M | 0.05M | 0.05M | 0.05M | 0.05M |
| Net Receivables | 21.065M | 13.693M | 6.089M | 5.667M | 3.139M |
| Long Term Debt | 0.742M | 1.789M | 2.803M | 5.058M | 1.983M |
| Inventory | 8.972M | 4.53M | 2.535M | 1.96M | 1.217M |
| Accounts Payable | 6.392M | 2.738M | 1.871M | 1.814M | 1.612M |
| Accumulated Other Comprehensive Income | -3.36M | -4.83M | -5.262M | -1.637M | -4.602M |
| Non Currrent Assets Other | 0.037M | 0.183M | 0.329M | 0.476M | -18.437M |
| Non Current Assets Total | 29.872M | 25.266M | 18.782M | 22.095M | 18.579M |
| Capital Lease Obligations | 12.75M | 12.857M | 6.861M | 2.414M | 2.744M |
| Long Term Debt Total | - | 14.154M | 9.207M | 7.122M | 4.404M |
Cash Flow
(Currency in AUD)| Breakdown | 30-06-2023 | 30-06-2022 | 30-06-2021 | 30-06-2020 | 30-06-2019 |
|---|---|---|---|---|---|
| Investments | -0.849M | 5.858M | -3.567M | -8.844M | 19M |
| Total Cashflows From Investing Activities | -0.849M | 5.858M | -3.567M | -8.844M | 13.061M |
| Total Cash From Financing Activities | 48.064M | -5.388M | -0.07M | 7.027M | 0.95M |
| Net Income | -4.925M | -1.193M | -4.605M | -4.194M | -3.19M |
| Change In Cash | 40.745M | -1.586M | -3.959M | -2.273M | 10.774M |
| Begin Period Cash Flow | 6.102M | 7.689M | 11.648M | 13.921M | 3.147M |
| End Period Cash Flow | 46.847M | 6.102M | 7.689M | 11.648M | 13.921M |
| Total Cash From Operating Activities | -6.613M | -2.057M | -0.25M | -0.427M | -3.37M |
| Depreciation | 2.283M | 1.797M | 1.116M | 0.837M | 0.31M |
| Other Cashflows From Investing Activities | 0.679M | 0M | 0.001M | 0.025M | 0.582M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -1.995M | -0.575M | -0.743M | -0.002M | -0.132M |
| Sale Purchase Of Stock | 52.051M | 0.18M | 0.18M | 0M | 0.95M |
| Other Cashflows From Financing Activities | -0.827M | 1.527M | 6.891M | 7.027M | 13.061M |
| Capital Expenditures | 1.528M | 0.492M | 3.569M | 8.869M | 6.52M |
| Change In Working Capital | -9.422M | -0.852M | -3.11M | -0.872M | 0.794M |
| Other Non Cash Items | -3.971M | -2.662M | 3.238M | 2.929M | 2.88M |
| Free Cash Flow | -8.141M | -2.549M | -3.819M | -9.297M | -9.89M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | iShares Core MSCI Total International Stock ETF | 4 years ago | 677246 |
| 2. | College Retirement Equities Fund-Stock Account | 4 years ago | 590586 |
| 3. | iShares Core MSCI EAFE ETF | 4 years ago | 3161650 |
| 4. | Vanguard International Stock Index-Total Intl Stock Indx | 4 years ago | 9342937 |
| 5. | Vanguard Tax Managed Fund-Vanguard Developed Markets Index Fund | 4 years ago | 3735528 |
| 6. | iShares MSCI EAFE Small Cap ETF | 4 years ago | 2452907 |
| 7. | Vanguard International Stock Index-Pacific Stock Index | 4 years ago | 593403 |
| 8. | SPDR Portfolio Developed World ex-US ETF | 4 years ago | 639132 |
| 9. | Vanguard Intl Equity Index Fds-FTSE All World ex U.S.Small Cap Index | 4 years ago | 1475300 |
| 10. | Schwab Strategic Tr-Schwab International Small Cap Equity ETF | 4 years ago | 812824 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...